P1044: REAL-WORLD RUXOLITINIB TREATMENT PATTERN IN MYELOFIBROSIS PATIENTS WITH THROMBOCYTOPENIA

por Mei, J., Wang, Y., Kabir, S., Ichikawa, N., Iino, S., Lebedinsky, C.
Publicado 2022

The Signature Program: Bringing the Protocol to the Patient

por Kang, BP, Slosberg, E, Snodgrass, S, Lebedinsky, C, Berry, DA, Corless, CL, Stein, S, Salvado, A
Publicado 2015

A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis

por Pardanani, A, Tefferi, A, Jamieson, C, Gabrail, N Y, Lebedinsky, C, Gao, G, Liu, F, Xu, C, Cao, H, Talpaz, M
Publicado 2015

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-...

por Poveda, A., Vergote, I., Tjulandin, S., Kong, B., Roy, M., Chan, S., Filipczyk-Cisarz, E., Hagberg, H., Kaye, S. B., Colombo, N., Lebedinsky, C., Parekh, T., Gómez, J., Park, Y. C., Alfaro, V., Monk, B. J.
Publicado 2011

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval

por Kaye, S. B., Colombo, N., Monk, B. J., Tjulandin, S., Kong, B., Roy, M., Chan, S., Filipczyk-Cisarz, E., Hagberg, H., Vergote, I., Lebedinsky, C., Parekh, T., Santabárbara, P., Park, Y. C., Nieto, A., Poveda, A.
Publicado 2011